A 52-year-old patient walked into my office last spring sixty-four pounds lighter than the year before, panicked about a five-pound regain. She had been on tirzepatide for fourteen months, hit her goal weight at month eleven, and her primary care doctor had tapered her off the medication entirely at month twelve with the instruction to "maintain with diet and exercise." Three months later the scale was creeping. She was eating the same way she had during the loss phase. Her labs had not been rechecked. Nobody had built her a maintenance plan because nobody had thought past the prescription.
I have had some version of this conversation more times than I can count over the last two years. The medications work. The loss is real. What collapses, predictably, is the year-two and year-three picture — because the program ended at the prescription instead of pivoting to a maintenance protocol that respects how the post-loss body actually behaves.
Why year two is harder than year one
The first year of medical weight loss is the easy year. Appetite suppression is doing real work, the patient is highly motivated by visible change, the protocol is structured and the appointments are frequent. Twelve months in, three things shift simultaneously and most patients are not warned about any of them.
First, the body has spent a year defending against fat loss. Resting metabolic rate drops more than the pure math of weight loss would predict — the adaptive component of metabolic adaptation is real, well-documented, and persists for years after the loss. A 52-year-old woman who was burning 1,650 calories at rest pre-treatment may be burning 1,350 at her new lower weight. That 300-calorie gap is what closes the door on "just keep doing what you were doing."
Second, the hormones that defend body weight upregulate. Ghrelin (the hunger signal) rises. Leptin (the satiety signal) drops in proportion to lost fat mass. The drive to eat increases. On medication, that drive is suppressed pharmacologically. Off medication, it is not — and the patient who was effortlessly eating 1,400 calories on tirzepatide is now fighting against a hunger signal that the medication used to silence.
Third, muscle mass loss during the rapid-loss phase reduces the metabolic floor further. This is the piece I see undertreated most often. Patients who lost 50 to 70 pounds without dedicated resistance training have usually lost 20 to 30 percent of that as lean mass, and lean mass is the tissue that burns calories at rest. Less muscle, lower RMR, harder maintenance.
Add those three together and you can see why the patients who hit a year and stop losing are not the patients in trouble. The patients in trouble are the ones who hit a year, stop the medication abruptly, and have no protocol for what comes next.
What "maintenance" actually means clinically
Maintenance is not the absence of treatment. It is a different treatment with different objectives. The goal shifts from creating a caloric deficit to defending the new metabolic setpoint against the body's defended-weight pressure.
A real maintenance plan has five components:
- A medication strategy — either a continued maintenance dose of the GLP-1, a planned step-down protocol with built-in reassessment intervals, or a structured off-medication plan with a clear re-entry trigger
- A protein and resistance training prescription specific enough to preserve and rebuild lean mass at the new weight
- A reassessment cadence that catches drift early — quarterly weights and labs for at least the first year off the loss protocol
- A coordinated workup of the hormonal and thyroid picture, because untreated hormonal contributors will undermine maintenance the same way they undermined the original weight
- A defined re-entry plan so the patient and the clinic both know what triggers a return to active loss versus what is normal post-loss fluctuation
When any of these is missing the maintenance phase usually fails. When all five are in place, the success rate looks completely different.
The mechanism — why GLP-1 maintenance dosing makes sense for many patients
The bias in 2026 is still toward thinking of GLP-1 medications as a discrete weight loss intervention with a defined endpoint. The physiology argues for thinking about them differently. Obesity behaves like a chronic relapsing condition. The body's defended weight does not reset to the new lower number just because the patient hit a goal — it continues to defend the higher pre-loss weight for a long time, possibly indefinitely. That is why discontinuation is followed by regain in a meaningful percentage of patients.
A maintenance dose of semaglutide or tirzepatide — often 0.25 to 0.5 mg of semaglutide weekly, or 2.5 to 5 mg of tirzepatide weekly, well below the loss-phase dose — provides enough ongoing appetite signaling support to hold the new weight without continuing aggressive loss. For patients who tolerate it, this is often the cleanest answer. For patients who want off the medication entirely, a deliberate taper with quarterly check-ins and a clear re-entry trigger is the next-best protocol.
What does not work is sudden discontinuation with no plan, which is the protocol that had my patient back in the office panicking about five pounds.
How I evaluate someone for the maintenance phase
Not sure where to start?
The Start Here pathway walks you through the most common entry points and helps you decide which consultation type is the right fit. Five minutes of self-assessment can save you a wrong-direction conversation.
The maintenance consultation is structured differently from the loss-phase consultation. By this point I already know the patient — their response curve, their tolerated dose range, their adjacent issues. The conversation is about translating what worked into a sustainable protocol.
I run a focused panel: full thyroid (TSH, free T4, free T3, reverse T3, antibodies), sex hormones with attention to the picture that emerges as fat mass drops (estrogen often shifts because adipose tissue converts androgens to estrogens), fasting insulin and HbA1c to confirm the metabolic improvement is sticking, lipid panel, ferritin and vitamin D, and a CBC. If the patient has not had body composition measured I order a DEXA — the scale weight is not enough information once we are past the loss phase, because the question is now what tissue compartment any future change is occurring in.
I also do a structured intake on three things that almost always need attention at this stage: protein intake (almost always too low — the target is 0.7 to 1.0 grams per pound of goal body weight, and most post-GLP-1 patients are eating half that), resistance training frequency and intensity (usually too occasional and too light to defend muscle), and sleep quality (often degraded during loss because rapid weight loss disrupts sleep architecture in ways most patients do not connect to the medication).
From the data and the intake, the maintenance plan writes itself. It usually involves a dose adjustment on the GLP-1, a protein and lifting prescription with measurable targets, hormone optimization where the panel shows treatable contributors, and structured nutritional counseling for the patients whose food relationship needs more support than a medication can provide.
Preserving muscle is the work of year two
If I had to pick one intervention that separates the patients who hold their loss from the ones who regain, it is muscle preservation. Lean mass is the metabolic floor. The patient who finished the loss phase with intact or improved lean mass has a defended floor that makes maintenance possible. The patient who finished with significantly reduced lean mass is fighting a structural metabolic disadvantage that no nutrition plan fully closes.
The protocol I run for muscle preservation in the maintenance phase is straightforward: protein at the high end of the recommended range distributed across at least three meals (the per-meal threshold for muscle protein synthesis matters, not just the daily total), resistance training three to four times weekly with progressive overload (machines and free weights both work, what matters is the load increase over time), and creatine monohydrate at 5 grams daily for patients without contraindications.
For patients in middle Georgia who are not gym-comfortable, the entry point is often a few sessions with a trainer at a gym in Columbus or Warner Robins to learn basic compound lifts safely. The investment pays back across the next decade in preserved metabolic function.
When the maintenance plan needs to escalate back to loss
Not every weight regain warrants restarting the loss-phase protocol. A 3 to 5 pound fluctuation in either direction is normal physiologic variation. A persistent upward trend over two consecutive monthly checks, or a 10-pound gain at any single check, is the trigger I use to revisit the protocol — usually with a dose increase on the GLP-1 or a return to the structured loss phase for a defined window.
Catching drift early is the entire game. A 5-pound recheck triggers a conversation. A 25-pound recheck triggers a much harder restart. The reassessment cadence in maintenance exists specifically to keep us in the first category and out of the second.
The plan past year three
The patients I have followed for two and three years on a structured maintenance protocol fall into two clean groups. The patients who stayed engaged with the program — quarterly checks, lab work twice a year, ongoing coordination with their hormonal and metabolic care — have largely held their loss with minor adjustments along the way. The patients who treated the program as one-and-done, regardless of how well the loss phase went, are over-represented in the regain group.
This is not unique to medical weight loss. Seventeen years in emergency medicine and cardiac care taught me the same lesson about hypertension, diabetes, and heart failure — they are ongoing relationships with a clinical team that catches drift before it becomes a crisis. Obesity behaves the same way.
What to bring to the maintenance consultation
If you are at or approaching the one-year mark on a GLP-1 protocol — whether through this clinic, another clinic, or a telehealth program — the highest-value next step is a structured maintenance consultation. Bring the full medication history (drug, doses, dates of escalation, side effects), the most recent labs you have, your current weight and the weight you started at, and any body composition data if you have it.
If you have already discontinued the medication and are watching the weight come back, bring the same information. The longer the gap before re-engagement, the more work the maintenance phase has to do, but the protocol is the same and the response is usually fast once we restart structured care.
You can book online for a maintenance-focused visit at the Columbus clinic or the Warner Robins clinic. The weight loss assessment is a useful pre-visit step if you want to think through where you fit before booking. Either way, the next step is data and a plan — not a different prescription pad.
Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. Individual clinical decisions should be made in consultation with a qualified healthcare provider following appropriate evaluation. References to specific treatments, dosing, or protocols are informational.
Travis spent 17+ years in high-acuity clinical medicine — emergency, cardiac ICU, and cath lab — before founding Revitalize. He is a Certified Platinum Biote hormone therapy provider, the published author of You're Not Broken — You're Unbalanced, and the founder of the Rebuild Metabolic Health Institute. His clinical writing reflects the same precision he brought to critical care: specific, honest, and built around what actually works.
Ready to talk it through with a clinician?
Book online or call either Georgia location. Every visit starts with a consultation.